Drug intelligence / Profile preview

SP1.5

Development stage: Preclinical
Lead developer: SASPiPhi
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intravenous

Overview

SP1.5 is an antibacterial therapeutic candidate being developed by SASPiPhi for the treatment of bloodstream infections caused by *Staphylococcus aureus*. The drug utilizes the proprietary SASPject platform, which employs engineered bacteriophages as delivery vectors to transport a gene encoding a Small Acid-Soluble Spore Protein (SASP) directly into target bacterial cells. Once the gene is delivered, the bacteria produce SASP, which binds non-specifically and tightly to the bacterial DNA. This binding effectively 'locks' the DNA, preventing replication and transcription, which leads to rapid bacterial cell death. This mechanism of action is independent of traditional antibiotic resistance pathways, making it potentially effective against multi-drug resistant strains such as MRSA.

Targets

bacterial dsDNA (Bacterial double-stranded DNA)

Beyond the preview

Go deeper on SP1.5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP1.5.

Explore the full profile